SBWire

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2014

Psoriatic Arthritis - Pipeline Review, H1 2014

Burns - Pipeline Review, H1 2014

ImQuest Life Sciences - Product Pipeline Review - 2014

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2014

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Merz Pharma GmbH & Co. KgaA - Product Pipeline Review - 2014

Ocular Hypertension - Pipeline Review, H1 2014

Sickle Cell Disease - Pipeline Review, H1 2014

GlobalData's clinical trial report, "Urethral Cancer Global Clinical Trials Review, H1, 2014" provides data on the Urethral Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Urethral Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Urethral Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Overactive Bladder - Pipeline Review, H1 2014

Chikungunya - Pipeline Review, H1 2014

Venous Thromboembolism - Pipeline Review, H1 2014

Pulmonary Arterial Hypertension - Pipeline Review, H1 2014

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability.

Conjunctivitis Partnering 2009-2014 report provides understanding and access to the conjunctivitis partnering deals and agreements entered into by the worlds leading healthcare companies.

Fibromyalgia - Pipeline Review, H1 2014

Metastatic Prostate Cancer - Pipeline Review, H1 2014

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Bausch & Lomb Incorporated - Product Pipeline Review - 2014

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014

Arthritis Partnering 2009-2014 report provides understanding and access to the arthritis partnering deals and agreements entered into by the worlds leading healthcare companies.

Ischemia Reperfusion Injury - Pipeline Review, H1 2014

Urinary Incontinence - Pipeline Review, H1 2014

Choroidal Neovascularization - Pipeline Review, H1 2014